| T0617 | Nicotinamide-N-oxide | Nicotinamide N-oxide is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes t |
| T3048 | 10058-F4 | 10058-F4 is a cell-permeable thiazolidinone that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle ar |
| T3686 | 10074-G5 | 10074-G5 is an inhibitor of c-Myc-Max dimerization. |
| T4367 | Mycro-3 | Mycro 3 is potent and selective for c-Myc in whole cell assays. |
| T4252 | ML327 | ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT). |
| TN2177 | Sanggenol L | Sanggenol L shows higher cytotoxicity against human oral tumor cell lines (HSC-2 and HSG) than against normal human gingival fibroblasts (HGF), it induces apoptosis via caspase act |
| TN1103 | Diphyllin | Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling. |
| TN1354 | Aaptamine | Aaptamine functions as a proteasome inhibitor, it activates p21 promoter in a p53-independent manner. |
| T12133 | MYCi975 | MYCi975 is an orally active inhibitor of MYC. |
| T10352 | APTO-253 | APTO-253 inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity |
| T10702 | CBP/EP300-IN-2 | CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc) extracted from patent WO2017205538A1 (example 25). |
| T15665 | KJ Pyr 9 | KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay). |
| T11783 | KSI-3716 | KSI-3716 is an inhibitor of c-Myc. |
| T16839 | sAJM589 | sAJM589 is a Myc inhibitor(IC50: 1.8 μM). |
| T12132 | MYCi361 | MYCi361 is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). |
| T3851 | Vicenin -2 | Vicenin -2 has hepatoprotective, anti-cancer, antioxidant and anti-inflammatory activities, and DTL co-administration is more effective than either of the single agents in androgen |
| TN3708 | Coronarin D | Coronarin D shows promising antifungal activity against C. albicans in vitro, the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) were 2 and 4 |
| TN4581 | Moracin D | Moracin C and moracin D, new phytoalexins from diseased mulberry, are antifungal compounds. Moracin may be protective influence in tumor promotion, utilization of Moracin may open |
| TN4582 | Moracin T | Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte in |
